Belite Bio Inc ADR (BLTE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Belite Bio Inc ADR (BLTE) has a cash flow conversion efficiency ratio of 0.000x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.38K) by net assets ($770.49 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Belite Bio Inc ADR to measure how many days the company can operate on defensive assets alone.
Belite Bio Inc ADR - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Belite Bio Inc ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Belite Bio Inc ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Belite Bio Inc ADR ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tsingtao Brewery Co Ltd
SHG:600600
|
0.032x |
|
Taiwan Glass Ind Corp
TW:1802
|
0.003x |
|
Accelleron Industries AG
SW:ACLN
|
0.290x |
|
Mohawk Industries Inc
NYSE:MHK
|
0.013x |
|
AIXTRON SE
XETRA:AIXA
|
0.060x |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
-0.943x |
|
MSA Safety
NYSE:MSA
|
0.056x |
|
Chime Financial, Inc. Class A Common Stock
NASDAQ:CHYM
|
0.061x |
Annual Cash Flow Conversion Efficiency for Belite Bio Inc ADR (2020–2025)
The table below shows the annual cash flow conversion efficiency of Belite Bio Inc ADR from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Belite Bio Inc ADR.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $770.49 Million | $-36.99 Million | -0.048x | +76.05% |
| 2024-12-31 | $145.82 Million | $-29.23 Million | -0.200x | +39.24% |
| 2023-12-31 | $90.43 Million | $-29.84 Million | -0.330x | -19.51% |
| 2022-12-31 | $41.50 Million | $-11.46 Million | -0.276x | -155.75% |
| 2021-12-31 | $-15.09 Million | $-7.47 Million | 0.495x | -21.55% |
| 2020-12-31 | $-7.04 Million | $-4.44 Million | 0.631x | -- |
About Belite Bio Inc ADR
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and … Read more